Dr Andrea Allmendinger
Chief Scientific Officer

Is this your profile?

About

Andrea Allmendinger, PhD, has been Chief Scientific Officer at ten23 health since November 2021. Dr Allmendinger is also Adjunct Professor and Group Leader at the University of Freiburg (Baden-Württemberg, Germany), researching novel parenteral drug formulations and device solutions to improve stability, usability and cost of goods. Between 2010 and 2021, she was Principal Scientist, Pharmaceutical Development at Roche, working on inter alia manufacturability and injectability of high-concentration formulations, syringe and high-volume drug/device combination products, particulates and surfactant strategy.

Dr Allmendinger studied Pharmacy at the University of Heidelberg (Germany) and University College London (UK), and holds a PhD in Pharmaceutical Sciences from the University of Basel (Switzerland). She obtained the venia legendi (German Habilitation) from the University of Freiburg in 2021 and served as Editor-In-Chief for the AAPS Open Journal from 2021 to 2024.

Contributions

TECHNICAL CHALLENGES DURING THE DEVELOPMENT OF ON-BODY INJECTORS

Andrea Allmendinger, Michael Adler, Carole Delauney and Hanns-Christian Mahler provide an overview of large-volume wearable injection devices for the subcutaneous delivery of biologics and discuss the technical challenges associated with the development and manufacturing of these drug/device combination products.

More contributions

TRANSITIONING FROM VIAL TO SUBCUTANEOUS INJECTION DEVICES FOR BIOLOGICAL DRUG PRODUCTS

Michael Adler, Venkata Appa Reddy Goli, Andrea Allmendinger and Hanns-Christian Mahler, discuss the various factors that need to be considered when transferring to a delivery device for subcutaneous injection, such as a prefilled syringe or autoinjector, during clinical trials or post-launch, especially when transferring from a vial format for intravenous infusion.

ADDRESSING INTRAVITREAL PRODUCT MANUFACTURING AND DEVELOPMENT CHALLENGES

Andrea Allmendinger, Hanns-Christian Mahler and Philipp Behrendt discuss the challenges of filling very small volumes into syringes for intravitreal injections, and how ten23’s innovative filling technology can help combat the critical issue of air bubble formation.

INDUSTRIALISATION

INTEGRATED DRUG PRODUCT DEVELOPMENT AND MANUFACTURING

Andrea Allmendinger; Michael Adler and Hanns-Christian Mahler highlight the importance of integrated drug product development, considering aspects such as formulation, device, container closure system, manufacturing processes and usability, as well as considering the quality target product profile and clinical phase-appropriate technical development strategy.

INTRAVITREAL INJECTIONS – MORE THAN MEETS THE EYE: A TECHNICAL VIEW OF PRODUCT USE

Andrea Allmendinger and Hanns-Christian Mahler highlight the technical challenges of intravitreal administration and considerations from the ophthalmologist’s and patient’s perspectives.

PREFILLED SYRINGES

ANTICIPATING & MITIGATING CHALLENGES IN THE COMMERCIALISATION OF PREFILLED SYRINGES & INJECTION DEVICES – A TECHNICAL DRUG PRODUCT PERSPECTIVE

Andrea Allmendinger and Hanns-Christian Mahler both at ten23 health, provide an insight into the challenges of integrated development of drug product and device design and fill-finish manufacturing operations.

HOW TEN23 HEALTH IS MEETING DEVELOPMENTAL CHALLENGES FOR INTRAVITREAL PRODUCTS

Andrea Allmendinger and Hanns-Christian Mahler highlight new regulatory and quality requirements for intravitreal applications and discuss technical challenges during drug product technical development and manufacturing.

Top